<DOC>
	<DOCNO>NCT00878293</DOCNO>
	<brief_summary>The purpose trial determine whether new centrally active analgesic MS ContinusÂ® effective treatment painful diabetic polyneuropathy .</brief_summary>
	<brief_title>Painful Diabetic Polyneuropathy Trial With New Centrally Acting Analgesic</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Subjects pain least NRS &gt; 4 due painful diabetic polyneuropaty . Contraindications , history allergy hypersensitivity morphine , fentanyl , hydrocodone , acetaminophen , heparin , polyethylene glycol 400 USPNF compound plan used anesthesia , excipients . non Caucasian Hispanic . Concomitant painful disease . Lifelong history seizure disorder epilepsy . Subjects clinical relevant cardiac vascular disease . Subjects impaired renal function Subjects impair hepatic function Female subject pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>analgesic</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>chronic neuropathic pain</keyword>
	<keyword>painful polyneuropathy cause diabetes mellitus type I II</keyword>
</DOC>